| Prev Close | 125.30 |
| Open | 124.81 |
| Day Low/High | 124.27 / 125.48 |
| 52 Wk Low/High | 100.34 / 129.70 |
| Volume | 3.05M |
Abbott Laboratories (ABT)
124.37
0.93
0.74
NYSE
| Exchange | NYSE |
| Shares Outstanding | 1772.82B |
| Market Cap | 220.98B |
| P/E Ratio | 60.02 |
| Div & Yield | N.A. (N.A) |
Latest News
Jim Cramer: The Fortunes Have Been Restored for Regeneron and Abbott
The tables have turned, their stocks have been up, and I think they go higher still.
Abbott Labs Is Poised to Break Out to New Highs
Let's check out the charts of ABT.
Jim Cramer: To Every Market Sector, Turn, Turn, Turn
To the melody of the Byrds' famed song, I want you to know: There's a time to buy the industrials, a time to sell the banks; a time to bid for health cares, a time to dump the techs. ...
Green Tuesday, Delta Economy, Policing Cryptos, Lockheed vs General Dynamics
The Delta virus has more power to control both fiscal and monetary policy than does the data or do any of our leaders individually.
3 High-Yield Dividend Aristocrats to Buy
These names have demonstrated over a long period they have the business models and growth prospects to raise their dividend payments each year.
Crypto Pep Rally, S&P Wonder Line, Minerd Unmuted, Chip Keepers, Trading Moderna
Small-caps and mid-caps are still picking first downs on every play, storming back from a badly oversold condition that has just about normalized.
A 5-Stock Healthcare Portfolio With a 5.5% Yield
These names offer appeal to both growth and dividend investors.
'All or None' Marketplace, Ransomware Beef, Trading AMC and Abbott Labs
Also, the ISM survey results showed us a few trends that at least appear as potential if not troubling question marks on the horizon.
A Mild and Mixed Market Favors Speculative Small-Caps
Probably the best news right now is that individual stock picking has improved.
Best Stocks With DRIP Plans Right Now
These Dividend Aristocrats have free DRIPs, long histories of raising their dividends, and attractive yields well above the market average.
Key Chart Favors a Nice Rise in Abbott Labs Later This Year
The technical signals indicate the odds of further weakness in the health care company's shares are low.
Investors on United Airlines Could See a Bumpy Ride Ahead
Consider other 'travel plans.'
New Moon on Monday, Fair Warning on Semis and Small-Caps, Ballad of Nvidia, IBM
Always, always, always stick to your rules. Always. This is why we have targets, pivots and panics.
We've Changed Our Strategy on Abbott Laboratories
The charts are more mixed now.
Revisiting an S&P 500 Chart Setup and Tracking 2 Stocks on Pullbacks
Microsoft and Abbott Laboratories are the names that are worth watching.
Jim Cramer: There's Good Risk and Bad Risk
Here's the kind I like to buy -- and the vetted stocks that you can play on 'good' risk.
Here's a Quick Technical Update on Abbott Laboratories
Traders should continue to hold existing longs on ABT.
Underperforming Transports, Vaccine Delivery, FOMC Statement, 3 Trading Thoughts
Wednesday afternoon the Fed's Federal Open Market Committee will publish the central bank's first official policy statement of 2021.
Abbott Labs Has the Formula for a Long Trade
ABT has made an upside breakout on the daily Point and Figure chart, and here's how investors can make their next move.
Jim Cramer: You Just Won Powerball, Now What?
Remember, you only need to get rich once.
8 Quality Dividend Stocks for Durable Growth and Income
Four experts highlight their favorite dividend stocks for 2021.
Jim Cramer: Misconceptions About Covid-19 and Wagering on Its Longevity
Maybe we will be better when Covid 2021 comes around. But sustainable? Ha. How about inevitable?
Abbott Laboratories Could Soon Break Out From Its Sideways Pattern
Let's review the charts and indicators.
Jim Cramer: 8 Stocks That Benefit the Most If There's Another Modified Lockdown
These companies have spent the last six months preparing for a second lockdown betting it will occur.
Jim Cramer: Health Care Stocks, the Election and the Perfect Setup
Right now, the market is furiously trying to price in a Blue Wave, and the health care sector is getting clobbered. But here's how I think things play out.
Does Abbott Labs Still Pass My Test After Earnings?
Diagnostics revenue grew an impressive 38% due to the necessity of Covid-19 testing.
'Inside Day', Electoral Risk, Banking Stocks, Stimulus Immediately Needed
There is a presidential debate on Thursday. The market is being forced to adjust for renewed potential uncertainty.
